Natera, Inc.

Public Equity (NASDAQ)PublicDiagnosticscfDNA

📍 Austin, TX, United States• Founded 2004

StreetZero Signal 65

Be the first to signal interest

About Natera, Inc.

Natera, Inc. (NASDAQ: NTRA) is a global leader in cell-free DNA (cfDNA) testing focused on oncology, women’s health, and organ health. The company aims to make personalized genetic testing and diagnostics part of the standard of care. It operates ISO 13485-certified and CAP-accredited laboratories in Austin, Texas and San Carlos, California. Natera’s tests are validated by more than 400 peer-reviewed publications.

LATEST FUNDINGRule 144

$3.9M

Announced 2026-10-21

TOTAL RAISED$152M

🔒

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for Natera, Inc..

Create free account Sign in

Free plan includes 3 full deal profiles every month.

IN THE NEWS

EMPLOYEES—

FOUNDED2004

HQAustin, TX, United States

Industry

Public Equity (NASDAQ)

Tags

PublicDiagnosticscfDNABiotech

Investors

Harmony Partners Bain Capital Life Sciences

Key highlights

Completed $107.5M IPO on NASDAQ.
Raised $250.3M and $551.2M via follow-on equity offerings.
Operates CAP-accredited labs in Austin, TX and San Carlos, CA.
Total pre-IPO funding reached $152M from 20 institutional investors.
Generated $665.5M revenue in Q4 2025, up 39.8% YoY.

Ask StreetZero about Natera, Inc.

Put our AI to work on this deal.

What is Natera, Inc.'s value proposition?Who are Natera, Inc.'s competitors?Why does this raise matter?Summarize Natera, Inc. for an investor.

Similar companies

Other Public Equity (NASDAQ) deals, ranked by Signal.

Crowdstrike Holdings, Inc.

Palo Alto Networks Inc

STOKE THERAPEUTICS, INC.

Lindblad Expeditions Holdings, Inc.

Source document & SEC filing

The source SEC filing and the cached document are available to members only. Sign in to view and download them.

Sign in to view the filing Create free account